EHA Unplugged
European Hematology Association
Andere apps
Pocket Casts Overcast Castro Castbox Podcast Addict AntennaPod RSS-feed
In these EHA-produced podcasts, experts share with you their hematology knowledge and stories. With "EHA Unplugged" we would like to give you the opportunity to unplug from your computer screen, while still learning, by listening to interviews, clinical cases, monologues, and more.
Afleveringen
-
Integrating Patient Perspectives Into Hematology Care (with Samantha Nier)
4 november 2026 · 12 min
The patient voice is no longer optional. Samantha Nier, Chair of the Patient Advocacy Committee (PAC) at EHA and a leader within the Acute Leukemia Advocates Network (ALAN) explains why clinical trials change for the better when patients are involved from the start. Lees meer
She highlights the importance of involving patients in clinical trial design, informed consent, and research protocols so that care decisions reflect not only scientific goals, but also real-life patient experience, quality of life, and treatment burden.
Samantha shows also how patient organizations contribute to many EHA initiatives, helping to shape guidelines, scientific congress sessions and European-level projects.
A thoughtful discussion about advocacy, inclusion, and the power of listening to the people most affected by disease.
Guests:
Samantha Nier
Affiliation: Chair of EHA's Patient Advocate Committee & Network Director of Acute Leukemia Advocates Network
Host:
Isabel Olivera-Martínez, PhD,
Medical Writer for EHA
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
-
How Experts Treat Follicular Lymphoma
30 oktober 2026 · 19 min
Follicular lymphoma (FL) is entering a new era: from decades of chemotherapy to increasingly effective, less toxic biological and immunotherapy-based approaches. Lees meer
In this podcast episode of EHA Unplugged, hear directly from the authors of the latest EHA guidelines on FL: Prof Marco Ladetto (University of Eastern Piedmont, Italy) and Prof Martin Dreyling (LMU Munich, Germany).
They start by discussing the importance of histological confirmation and grading, the role—and current limits—of molecular profiling, and how FLIPI-based risk assessment can inform treatment intensity.
The conversation covers active surveillance for asymptomatic disease, first-line immunochemotherapy, chemo-free options such as rituximab–lenalidomide and novel antibody-based combinations, and sequencing CAR T-cell therapy and bispecific antibodies in later relapses.
The experts also address survivorship, long-term toxicity, patient preferences, and the strategic need to preserve effective options across a potentially decades-long disease course.
Tune in for practical, evidence-based insights to support individualised follicular lymphoma care.
Guests:
Prof Marco Ladetto
University of Eastern Piedmont and SCDU Ematologia, Alessandria, Italy
Prof Martin Dreyling
Ludwig-Maximilian-University, Munich, Germany
Host:
Isabel Olivera-Martínez, PhD,
Medical Writer for EHA
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook…
-
How Experts Treat Chronic Lymphocytic Leukemia (CLL)
16 oktober 2026 · 15 min
Explore the latest EHA guidelines on chronic lymphocytic leukemia (CLL) and Richter transformation with key guideline authors Prof Barbara Eichhorst, hematologist at University Hospital Cologne (Germany), and Prof Paolo Ghia, Director of the CLL Program at Università Vita-Salute San Raffaele (Milan, Italy). Lees meer
For the first time, the guidelines no longer recommend chemoimmunotherapy when targeted options are available, based on two key advances: the approval of acalabrutinib plus venetoclax with or without obinutuzumab for frontline CLL, and the approval of pirtobrutinib, a non-covalent BTK inhibitor, for relapsed/refractory disease—particularly after prior covalent BTK inhibitor treatment. The guests also make clear that patient selection matters, including TP53 status, IGHV status, comorbidities, co-medications, safety profile, and patient preferences.
Further, the experts highlight a landmark change in how the recommendations were developed: for the first time, patients and patient advocates participated as authors, bringing a patient-centred perspective to treatment decisions, active surveillance, and supportive care.
Tune in for practical insights into personalized CLL management, fixed-duration targeted therapy, treatment sequencing, and the challenges of Richter transformation.
Guests:
Prof Barbara Eichhorst
University of Cologne, Cologne, Germany
Prof Paolo Ghia
Università Vita-Salute San Raffaele, Milano, Italy
Host:
Isabel Olivera-Martínez, PhD,
Medical Writer for EHA
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: …
-
How Experts Treat Hodgkin Lymphoma
9 oktober 2026 · 12 min
Stay up to date with the latest EHA guidelines on Hodgkin lymphoma. In this episode of EHA Unplugged, key guideline authors Prof. Dennis Eichenauer and Prof. Igor Aurer discuss the evidence reshaping the management of classic Hodgkin lymphoma. Lees meer
The discussion highlights the guideline’s central shift: the integration of targeted therapies—brentuximab vedotin and PD-1 inhibitors such as nivolumab—into frontline treatment. The experts explain updated approaches to staging and risk assessment, PET-guided treatment in early-stage disease, BrECADD for younger patients with advanced disease, and nivolumab–AVD for older patients, alongside recommendations for relapsed or refractory disease and autologous stem cell transplantation.
They also consider survivorship, late effects, and the realistic prospects for chemotherapy-free, immune-based approaches.
Tune in for practical, evidence-based insights into improving outcomes while reducing long-term toxicity in Hodgkin lymphoma.
Guests:
Prof. Dennis Eichenauer: University of Cologne, Germany;
First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, German Hodgkin Study Group, University of Cologne, Cologne, Germany
Prof. Igor Aurer: University Hospital Centre Zagreb, and Medical School, University of Zagreb, Zagreb, Croatia
Host:
Nabil Dorkhom, MD / EHA Head of Education
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook…
-
How to Improve Equity and Inclusion in Hematology: EHA2026 Diversity, Equity and Inclusion Award
2 oktober 2026 · 15 min
In this episode, Prof Gianluca Gaidano, recipient of the EHA2026 Diversity, Equity and Inclusion Award, explores how promoting equity, inclusion, and access to care has shaped his work within EHA and beyond. He reflects on educational initiatives in underrepresented regions, including Africa, the Middle East, Asia, and South America, and explains how international collaborations can help expand access to medical knowledge, advanced diagnostics, and innovative therapies. Lees meer
The discussion explores the difference between drug availability and true patient access, the role of education and patient advocacy in reducing disparities, and how partnerships with local hematology communities can strengthen clinical practice. Prof Gaidano also shares examples from countries such as Bangladesh, Iraq, and Albania, highlighting progress in access to diagnostics, treatments, and specialist training. Listen now for insights into how to contribute to building a more equitable future for hematology.
Guest: Prof Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont and Ospedale Maggiore della Carità, Novara, Italy
Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via …
-
Advancing Adult ALL Care in Europe: EHA2026 Clinical Excellence Award
25 september 2026 · 21 min
In this episode, Professor Josep-María Ribera, recipient of the EHA2026 Clinical Excellence Award, reflects on his career dedicated to adult acute lymphoblastic leukemia (ALL) and the advances that have transformed patient outcomes. He discusses the evolution of treatment for Philadelphia chromosome-positive ALL, from poor survival rates to highly effective targeted and immunotherapy-based approaches, and explains how tyrosine kinase inhibitors, blinatumomab, and chemotherapy-sparing strategies are reshaping care. Lees meer
The discussion also explores the growing role of measurable residual disease (MRD) monitoring and genetic risk stratification in treatment decision-making, including identifying which patients can safely avoid allogeneic stem cell transplantation. Professor Ribera highlights the impact of collaborative research through PETHEMA, EWALL, and EHA, and shares his perspective on the future of hematology. Listen now for insights into the progress of ALL treatment and a message of optimism for patients and clinicians alike.
Guest: Prof Josep-María Ribera
Josep Carreras Leukemia Research Institute (IJC) and Universitat Autònoma de Barcelona, Spain
Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Edu…
-
Refining Transplantation and Cellular Therapy: Insights from 2026 Young EHA Award Winner Nico Gagelmann
22 september 2026 · 23 min
In this episode, Dr Nico Gagelmann, recipient of the 2026 Young EHA Award, discusses his career in stem cell transplantation and the values that have shaped his work. He explains how multidisciplinary care, patient selection, graft-versus-host disease prevention, and conditioning strategies can help improve transplant outcomes. The discussion also explores the role of real-world evidence in identifying best practices and supporting efforts to harmonize transplantation approaches across centres. Lees meer
Dr Gagelmann also highlights the evolving role of CAR T-cell therapy, ongoing disparities in access to innovative treatments, and the importance of collaboration, education, and knowledge sharing across countries. He reflects on building international professional communities, addressing inequalities in hematology care, and ensuring that future advances remain accessible to patients. Listen now for insights into the future of transplantation, cellular therapies, and global hematology collaboration.
Guest: Dr Nico Gagelmann, Dana-Farber Cancer Institute, Boston, Massachusetts, USA, and University Medical Center Hamburg-Eppendorf, Germany
Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via …
-
What Can We Learn About AML from Clonal Haematopoiesis? | EHA 2026 Research Excellence Award
18 september 2026 · 22 min
In this episode, Prof George Vassiliou, recipient of the 2026 EHA Research Excellence Award, discusses how his research has advanced our understanding of clonal haematopoiesis and its relationship to acute myeloid leukaemia (AML). He explains how blood stem cells evolve over time, why specific driver mutations promote clonal expansion, and how genetic profiles can help identify individuals at low, intermediate, or high risk of developing myeloid malignancies. Lees meer
The discussion also explores efforts to translate these discoveries into clinical prevention strategies. Prof Vassiliou highlights emerging risk prediction models, the development of clinics focused on clonal haematopoiesis, and ongoing work to evaluate low-toxicity interventions that could reduce disease progression. He also examines the links between clonal haematopoiesis, cardiovascular disease, immune ageing, and age-related health outcomes, offering insights into the future of early detection and preventive approaches in haematology. Listen now for perspectives on how understanding clonal haematopoiesis may help reshape the prevention of AML and other age-related diseases.
Guest: Prof George Vassiliou, Department of Haematology and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linke…
-
Improving MPNs management: EHA2026 Lifetime Achievement Award
15 september 2026 · 21 min
In this episode, EHA 2026 Lifetime Achievement Award recipient Prof Claire Harrison reflects on a career dedicated to advancing the understanding and management of myeloproliferative neoplasms (MPNs). She reviews the major scientific and clinical developments she has witnessed over more than two decades, including the discovery of JAK2, MPL and CALR mutations, the evolution of diagnostic criteria, and the emergence of targeted therapies for MPNs. Lees meer
The discussion explores landmark studies that helped shape current clinical practice, including PT-1, COMFORT-II and MAJIC-PV, as well as the growing role of patient advocacy in driving research and improving care. Prof Harrison also looks ahead to the next generation of therapies, including CALR-targeted immune approaches and combination treatment strategies, while highlighting the challenges and opportunities that remain for patients with MPNs. Listen now for insights from one of the leading figures in the field.
Guest: Prof Claire Harrison
Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
-
CAR T Toxicities in Focus: What We Have Learned from Registry Data
9 september 2026 · 18 min
In this episode, Dr Annalisa Ruggeri discusses how registry data are helping clinicians better understand, monitor and manage CAR T-related toxicities. She explains how insights from more than 16,000 patients recorded in the European Bone Marrow Transplant Registry (EBMT), have helped improve early toxicities such as cytokine release syndrome (CRS) and ICANS awareness and management as well as helped recognise and address longer-term effects. She further explores the growing understanding of immune effector cell-associated hematotoxicity (ICAHT) and the importance of risk prediction and early intervention. Lees meer
Dr Ruggeri also discusses emerging safety questions as CAR T use expands, including secondary malignancies, long-term immune effects, and fertility outcomes. She highlights encouraging registry findings showing that fertility recovery and successful pregnancies are possible after CAR T therapy, offering renewed hope for patients seeking to return to normal life following treatment. Listen now for valuable insights into how registries, collaboration and long-term follow-up are helping improve cellular therapy.
Guest:
Dr Annalisa Ruggeri
Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
Chair of the Cellular Therapy and Immunobiology Working Party (Education Portfolio), EBMT
Host: Leah DeLeon
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://…
Vergelijkbare podcasts
-
NTVG PODCAST
Nederlands Tijdschrift Voor Geneeskunde
Laatste aflevering 15 oktober 2026
-
Huberman Lab
Scicomm Media
Laatste aflevering 5 november 2026
-
Focus op Wetenschap
NPO Luister / NTR
Laatste aflevering 2 november 2026
-
Diagnostiek dialogen
Unilabs
Laatste aflevering 22 april 2026
-
NRC Het Uur
NRC
Laatste aflevering 30 oktober 2026
-
Pioniers van de Wetenschap
Pieter Vancamp & Lucas Mergan
Laatste aflevering 7 oktober 2026
- Categorieën
- Wetenschap , Levenswetenschappen
- Status
- Loopt nog
- Verschijnt
- Een paar keer per week
- Lengte
- Meestal 20 min
- Afleveringen
- 203
- Laatste aflevering
- 4 november 2026
- Eerste aflevering
- 1 september 2021
- Taal
- Engels